Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has provided an update.
Fusen Pharmaceutical Co., Ltd. has announced a board meeting scheduled for August 29, 2025, to review and approve the company’s unaudited interim results for the first half of the year and to consider declaring an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 337,230
Technical Sentiment Signal: Sell
Current Market Cap: HK$261M
For detailed information about 1652 stock, go to TipRanks’ Stock Analysis page.